PLAN-LES-OUATES, Switzerland-(BUSINESS WIRE)

NovImmune, an antibody-focused research and development biotech company, announced today that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. Recently, the IL-17 signaling pathway has received significant academic and corporate interest as its manipulation may potentially provide new treatment opportunities for major medical conditions.

The anti-IL-17 antibody was generated by NovImmune’s research team and is currently in late preclinical development. Under the terms of the agreement NovImmune will receive an upfront payment and is eligible to receive clinical milestones and royalties on sales. Full financial terms have not been disclosed.

More details

Find an actor

BioAlps Networking Day 2017 November 21, 201721.11.2017

Nous avons le plaisir de vous annoncer le thème de l'édition 2017: NOVEMBER 21st, 2017 13:30-19:30 ...

UNRAVELLING THE SECRETS OF THE BRAIN

Bilan and BioAlps special webdoc edition
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn